finance.yahoo.com ·
recursion pharmaceuticals rxrx 10 unrivaled 173848347
Topic context
This topic has been covered 339151 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedRecursion Pharmaceuticals, an AI-driven drug discovery company, reported a significant revenue miss, indicating weak near-term commercial traction. However, its AI platform and clinical pipeline (REC-1245, REC-4539) represent long-term potential. The cash burn and lowered price target suggest financial pressure, but JPMorgan's Overweight rating signals confidence in the platform's value. The commercial mechanism is weak: no direct product price impact, supply chain disruption, or margin squeeze; the impact is company-specific, affecting RXRX equity valuation and investor sentiment.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Recursion Pharmaceuticals Q1 revenue $6.47M vs expected $15.78M
- Cash balance $665.2M, down from $753.9M at end of 2025
- JPMorgan lowered price target from $11 to $10, maintains Overweight
- CEO highlighted progress in REC-1245 and REC-4539 clinical programs
- Stock price $3.32
Pipeline progress and cash position offset revenue miss; sector impact neutral over 1-4 weeks.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- PHARMA_BIOTECHmid
- PHARMA_BIOTECHshort
Related stories
finance.yahoo.com
ncmi q1 2026 earnings transcript 154748256
finance.yahoo.com
transcript valneva q1 2026 earnings 155143868
fool.com
halozyme halo q1 2026 earnings transcript
economictimes.indiatimes.com
the rs 3 relief that wasnt why investors are dumping oil stocks after long awaited petrol diesel price hike
finance.yahoo.com